source
- FDA finds Replimune's melanoma data package uninterpretable, foreshadows tough advisory committee reviewThe FDA has deemed the single-arm mid-stage study submitted by Replimune for its oncolytic immunotherapy RP1 as not interpretable, raising concerns ahead of an upcoming advisory committee meeting.…
- Apnimed targets up to $160 million IPO to fund sleep‑apnea drug AD109Apnimed, a sleep‑specialist biotech, announced plans for an initial public offering that could raise up to $160 million in gross proceeds. The company will sell 10 million shares at $14‑$16 each,…